Sarepta Therapeutics Set to Join S&P MidCap 400
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500, Nasdaq advance as soft inflation tempers Fed rate-hike bets
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
Goldman Sachs Reinstates Johnson & Johnson (JNJ) at Neutral
May 30, 2024 7:25 AM EDTGoldman Sachs analyst Chris Shibutani reinstates coverage on Johnson & Johnson (NYSE: JNJ) with a Neutral rating and a price target of $160.00.
The analyst comments "We reinstate a rating on JNJ at Neutral. Over the near term (2024/25) we expect that JNJ's revenue and earnings growth is likely to remain tethered at relatively modest low single-digit levels,... More
